ClinicalTrials.gg
RecruitingNCT06342440AACRCUpdated Jul 7, 2026

Early Detection of Advanced Adenomas and Colorectal Cancer

An observational study in Colorectal Cancer, Colorectal Neoplasms and Colorectal Polyp, sponsored by City of Hope Medical Center. Recruiting at 6 sites in 5 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by City of Hope Medical Center · Observational

How we know

From the registry’s dates

  • Started Mar 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Colorectal Neoplasms by City of Hope Medical Center — 17 open to participants now, 22 under way, 2 of them phase 3. Colorectal Neoplasms · City of Hope Medical Center.

Planned enrollment
Largest of 14
2,000 · median 400
Started
2020
with 5 others
Observational
14 of 42
8 open now
Primary completion
2028-06
later than 10 of 21 live
Registered
26th of 42
by date

Among the 42 studies in Colorectal Neoplasms by City of Hope Medical Center, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 6 that started in 2020, is one of 14 observational ones, reaches primary completion later than 10 of the 21 other live ones, and was the 26th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

17 of the 42 studies in Colorectal Neoplasms by City of Hope Medical Center are open now, in 5 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Colorectal Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.

Read the detailed description

Colorectal cancer (CRC) is a significant global health concern, ranking third in diagnosis and second in mortality. Despite being potentially preventable, it remains a leading cause of cancer-related deaths. Traditional screening methods like fecal immunochemical testing (FIT) have shown benefits in reducing late-stage diagnoses but have not effectively prevented CRC incidence. This is because tests like FIT can effectively detect the cancers, but not the precursor lesions, called adenomas. On the other hand, endoscopy-first approaches offer higher sensitivity for such adenomas and, therefore, lower the risk of developing CRC but face challenges such as invasiveness, cost, and patient compliance.

Non-invasive tests are more appealing to patients than invasive tests and can increase participation rates. Biomarker studies have shown promise, but existing tests lack sensitivity for early-stage CRC and advanced adenomas (AAs). This is likely because they assume the same analyte can detect both CRC and AAs, which may not be accurate due to differences in analyte release and the biological changes that occur during the adenoma-carcinoma sequence.

This study proposes developing an innovative liquid biopsy test tailored for AAs and CRC to address this. An ideal screening test should be minimally invasive, highly sensitive, and cost-effective. This test would optimize patient compliance and resource allocation by detecting both conditions from a single blood draw. More specifically, circulating microRNA (miRNA) analysis shows promise: tests based on cell-free microRNA (cf-miRNA) have demonstrated high sensitivity, while those based on exosome-derived microRNA (exo-miRNA) offer high specificity. Therefore, combining both analytes in a single test could maximize sensitivity and specificity.

This study will develop a non-invasive blood test for AA and CRC in four phases:

  1. Genome-wide profiling of cf-miRNA and exo-miRNA and selecting the best candidates for biomarker panels.
  2. Utilizing machine learning to identify promising candidates and train algorithms for detecting AAs and CRC separately, based on results from quantitative polymerase chain reaction (qPCR) analysis.
  3. Combining these algorithms to create detection signatures for both conditions.
  4. Independently validating these signatures using diverse cohorts to ensure broad applicability and compare the effectiveness of the blood assay to standard care through retrospective and prospective studies.

This study aims to develop a highly sensitive, specific, and cost-effective liquid biopsy for early detection of AAs and CRC. Success could transform clinical practice by preventing CRC through early detection of pre-malignant lesions. Innovations include incorporating pre-malignant lesions into screening and combining cf-miRNA and exo-miRNA biomarkers for accuracy. This approach could reduce CRC mortality and incidence and pave the way for new clinical trials.

03

Conditions studied

  • Colorectal Cancer
  • Colorectal Neoplasms
  • Colorectal Polyp
  • Colorectal Adenocarcinoma
  • Colorectal Disorders
  • Colorectal Dysplasia
  • Colorectal Cancer Stage I
  • Colorectal Cancer Stage II
  • Colorectal Cancer Stage III
  • Colorectal Cancer Stage IV
  • Colorectal Neoplasms Malignant
  • Colorectal Serrated Adenocarcinoma
  • Colorectal Adenoma With Severe Dysplasia
  • Colorectal Adenoma With Mild Dysplasia
  • Colorectal Adenoma With Moderate Dysplasia
  • Colorectal Adenoma and Carcinoma 1
  • Colorectal Adenomatous Polyp
  • Colorectal Adenocarcinoma Metastatic in the Liver

Keywords

  • Early detection
  • Micro RNA
  • miRNA
  • Liquid biopsy
  • Machine learning
  • Artificial Intelligence
  • Incidence
  • Polypectomy
  • Screening
  • Surveillance
  • Exosome
  • Vascicles
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Three independent cohorts of individuals who belong to one of the following four

  • Negative colonoscopy findings
  • Low-risk adenomas (at most)
  • Advanced adenomas (at most)
  • Colorectal cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All individuals included in the study need to have had a colonoscopy at the time of blood sampling.
  • Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
  • Received standard pathological and endoscopic diagnosis and assessment for cohort assignment.

Exclusion criteria

Exclusion Criteria:

  • Hereditary colorectal cancer syndromes (identified through genetic testing).
  • Inflammatory bowel diseases.
  • Lack of written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Non-disease controls (Discovery cohort)

    Individuals who underwent colonoscopy and were found not to have any adenomas or cancer.

  • Low-risk Adenoma (Discovery cohort)

    Individuals who underwent colonoscopy and were found to only have low-risk adenomas, defined as all of the following: * 1 to 4 adenomas at most. * All adenomas have low-grade dysplasia at most. * All adenomas are \<10 mm in diameter

  • Advanced Adenoma (Discovery cohort)

    Individuals who underwent colonoscopy and were found to have high-risk adenomas, defined as one or more of the following: * 5 or more adenomas. * One or more adenomas have high-grade dysplasia. * One or more adenomas are \>10 mm in diameter

  • Colorectal Cancer (Discovery cohort)

    Individuals who underwent colonoscopy and were found to have colorectal cancer.

  • Non-disease controls (Training cohort)

    Individuals who underwent colonoscopy and were found not to have any adenomas or cancer.

    Diagnostic Test: DENEB

  • Low-risk Adenoma (Training cohort)

    Individuals who underwent colonoscopy and were found to only have low-risk adenomas, defined as: * 1 to 4 adenomas at most. * All adenomas have low-grade dysplasia at most. * All adenomas are \<10 mm in diameter.

    Diagnostic Test: DENEB

  • Advanced Adenoma (Training cohort)

    Individuals who underwent colonoscopy and were found to have high-risk adenomas, defined as one or more of the following: * 5 or more adenomas. * One or more adenomas have high-grade dysplasia. * One or more adenomas are \>10 mm in diameter.

    Diagnostic Test: DENEB

  • Colorectal Cancer (Training cohort)

    Individuals who underwent colonoscopy and were found to have colorectal cancer.

    Diagnostic Test: DENEB

  • Non-disease controls (Validation cohort)

    Individuals who underwent colonoscopy and were found not to have any adenomas or cancer.

    Diagnostic Test: DENEB

  • Low-risk Adenoma (Validation cohort)

    Individuals who underwent colonoscopy and were found to only have low-risk adenomas, defined as: * 1 to 4 adenomas at most. * All adenomas have low-grade dysplasia at most. * All adenomas are \<10 mm in diameter.

    Diagnostic Test: DENEB

  • Advanced Adenoma (Validation cohort)

    Individuals who underwent colonoscopy and were found to have high-risk adenomas, defined as one or more of the following: * 5 or more adenomas. * One or more adenomas have high-grade dysplasia. * One or more adenomas are \>10 mm in diameter.

    Diagnostic Test: DENEB

  • Colorectal Cancer (Validation cohort)

    Individuals who underwent colonoscopy and were found to have colorectal cancer.

    Diagnostic Test: DENEB

Interventions

  • Diagnostic testDENEB

    A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.

    Also known as: DENEB (DEtection of colorectal NEoplasias in Blood)

06

What researchers measure

Primary outcomes

  1. Sensitivity

    True positive rate: the probability of a positive test result, conditioned on the individual truly being positive

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Specificity

    True negative rate: the probability of a negative test result, conditioned on the individual truly being negative

    Time frame: Through study completion, an average of 1 year

  2. Proportion of correct predictions (true positives and true negatives) among the total number of cases (i.e., accuracy)

    A measure of trueness: proportion of correct predictions (both true positives and true negatives) among the total number of cases examined

    Time frame: Through study completion, an average of 1 year

07

Study locations

6 of 6 sites recruiting
  • City of Hope Medical Center
    Monrovia, California 91016, United States
    Recruiting
    • Ajay Goel, PhD · ContactAJGOEL@COH.ORG · 626-218-3452
    • Ajay Goel, PhD · Principal investigator
    • Caiming Xu · Sub investigator
    • Alessandro Mannucci · Sub investigator
    • James Lin · Sub investigator
    • Gregory Idos · Sub investigator
    • Trilokesh Kadambi · Sub investigator
  • University of California San Diego
    San Diego, California 92093, United States
    Recruiting
    • C Richard Boland, MD, PhD · Contact
    • C Richard Boland, MD, PhD · Sub investigator
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, China
    Recruiting
    • Jing Zhang · Contact
    • Jing Zhang · Sub investigator
    • Caiming Xu · Sub investigator
  • IRCCS San Raffaele
    Milan, Italy
    Recruiting
    • Giulia Martina Cavestro, MD, PhD · Contactcavestro.giuliamartina@hsr.it
    • Giulia Martina Cavestro · Sub investigator
    • Alessandro Mannucci · Sub investigator
  • Mie University
    Mie, Japan
    Recruiting
    • Yuji Toiyama · Contact
    • Yuji Toiyama · Sub investigator
    • Yoshinaga Okugawa · Sub investigator
    • Tadanobu Shimura · Sub investigator
  • Barcelona University
    Barcelona, Spain
    Recruiting
    • Francesc Balaguer, MD, PhD · Contactfprunes@clinic.cat
    • Francesc Balaguer · Sub investigator
    • Miguel Pera · Sub investigator
    • Lorena Moreno · Sub investigator
    • Luis Bujanda · Sub investigator
08

References and documents

Publications

  • Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008 Oct 7;149(7):441-50, W81. doi: 10.7326/0003-4819-149-7-200810070-00004. PubMed 18838724 ↗
  • Aziz Z, Wagner S, Agyekum A, Pumpalova YS, Prest M, Lim F, Rustgi S, Kastrinos F, Grady WM, Hur C. Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening in Patients Who Are Unscreened. JAMA Netw Open. 2023 Nov 1;6(11):e2343392. doi: 10.1001/jamanetworkopen.2023.43392. PubMed 37971743 ↗
  • Barnell EK, Kang Y, Wurtzler EM, Griffith M, Chaudhuri AA, Griffith OL; Geneoscopy Scientists. Noninvasive Detection of High-Risk Adenomas Using Stool-Derived Eukaryotic RNA Sequences as Biomarkers. Gastroenterology. 2019 Sep;157(3):884-887.e3. doi: 10.1053/j.gastro.2019.05.058. Epub 2019 May 30. No abstract available. PubMed 31154021 ↗
  • Barnell EK, Wurtzler EM, La Rocca J, Fitzgerald T, Petrone J, Hao Y, Kang Y, Holmes FL, Lieberman DA. Multitarget Stool RNA Test for Colorectal Cancer Screening. JAMA. 2023 Nov 14;330(18):1760-1768. doi: 10.1001/jama.2023.22231. PubMed 37870871 ↗
  • Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094. PubMed 24553385 ↗
  • Bosch LJW, de Wit M, Pham TV, Coupe VMH, Hiemstra AC, Piersma SR, Oudgenoeg G, Scheffer GL, Mongera S, Sive Droste JT, Oort FA, van Turenhout ST, Larbi IB, Louwagie J, van Criekinge W, van der Hulst RWM, Mulder CJJ, Carvalho B, Fijneman RJA, Jimenez CR, Meijer GA. Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study. Ann Intern Med. 2017 Dec 19;167(12):855-866. doi: 10.7326/M17-1068. Epub 2017 Nov 21. PubMed 29159365 ↗
  • Brenner H, Heisser T, Cardoso R, Hoffmeister M. Reduction in colorectal cancer incidence by screening endoscopy. Nat Rev Gastroenterol Hepatol. 2024 Feb;21(2):125-133. doi: 10.1038/s41575-023-00847-3. Epub 2023 Oct 4. PubMed 37794234 ↗
  • Carethers JM. Stool-Based Screening Tests for Colorectal Cancer. JAMA. 2023 Mar 14;329(10):839-840. doi: 10.1001/jama.2023.0547. PubMed 36800187 ↗
  • Carethers JM. Improving Noninvasive Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14;390(11):1045-1046. doi: 10.1056/NEJMe2400366. No abstract available. PubMed 38477992 ↗
  • Chung DC, Gray DM 2nd, Singh H, Issaka RB, Raymond VM, Eagle C, Hu S, Chudova DI, Talasaz A, Greenson JK, Sinicrope FA, Gupta S, Grady WM. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14;390(11):973-983. doi: 10.1056/NEJMoa2304714. PubMed 38477985 ↗
  • Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castanos-Velez E, Blumenstein BA, Rosch T, Osborn N, Snover D, Day RW, Ransohoff DF; PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014 Feb;63(2):317-25. doi: 10.1136/gutjnl-2012-304149. Epub 2013 Feb 13. PubMed 23408352 ↗
  • de Klaver W, Wisse PHA, van Wifferen F, Bosch LJW, Jimenez CR, van der Hulst RWM, Fijneman RJA, Kuipers EJ, Greuter MJE, Carvalho B, Spaander MCW, Dekker E, Coupe VMH, de Wit M, Meijer GA. Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening : A Diagnostic Test Accuracy Study. Ann Intern Med. 2021 Sep;174(9):1224-1231. doi: 10.7326/M20-8270. Epub 2021 Jul 20. PubMed 34280333 ↗
  • de Klerk CM, Wieten E, Lansdorp-Vogelaar I, Bossuyt PM, Spaander MC, Dekker E. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme. Lancet Gastroenterol Hepatol. 2019 Feb;4(2):111-118. doi: 10.1016/S2468-1253(18)30319-4. Epub 2018 Nov 27. PubMed 30497962 ↗
  • Fu B, Yan P, Zhang S, Lu Y, Pan L, Tang W, Chen S, Chen S, Zhang A, Liu W. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer. Dis Markers. 2018 Apr 23;2018:6437104. doi: 10.1155/2018/6437104. eCollection 2018. PubMed 29849824 ↗
  • Gagrat ZD, Krockenberger M, Bhattacharya A, Gagrat BZ, Leduc CM, Matter MB, Fourrier KD, Mahoney DW, Edwards V DK, Lidgard GP, Limburg PJ, Johnson SC, Domanico MJ, Kisiel JB. Next-generation Multi-target Stool DNA Panel Accurately Detects Colorectal Cancer and Advanced Precancerous Lesions. Cancer Prev Res (Phila). 2024 Mar 4;17(3):119-126. doi: 10.1158/1940-6207.CAPR-23-0285. PubMed 38224564 ↗
  • Grobbee EJ, Wisse PHA, Schreuders EH, van Roon A, van Dam L, Zauber AG, Lansdorp-Vogelaar I, Bramer W, Berhane S, Deeks JJ, Steyerberg EW, van Leerdam ME, Spaander MC, Kuipers EJ. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals. Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2. PubMed 35665911 ↗
  • Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, Robertson DJ, Shaukat A, Syngal S, Rex DK. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc. 2020 Mar;91(3):463-485.e5. doi: 10.1016/j.gie.2020.01.014. Epub 2020 Feb 7. No abstract available. PubMed 32044106 ↗
  • Imperiale TF, Gruber RN, Stump TE, Emmett TW, Monahan PO. Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps: A Systematic Review and Meta-analysis. Ann Intern Med. 2019 Mar 5;170(5):319-329. doi: 10.7326/M18-2390. Epub 2019 Feb 26. PubMed 30802902 ↗
  • Imperiale TF, Kisiel JB, Itzkowitz SH, Scheu B, Duimstra EK, Statz S, Berger BM, Limburg PJ. Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45-49 Year-Olds: A Cross-Sectional Study. Cancer Prev Res (Phila). 2021 Apr;14(4):489-496. doi: 10.1158/1940-6207.CAPR-20-0294. Epub 2021 Jan 12. PubMed 33436397 ↗
  • Imperiale TF, Porter K, Zella J, Gagrat ZD, Olson MC, Statz S, Garces J, Lavin PT, Aguilar H, Brinberg D, Berkelhammer C, Kisiel JB, Limburg PJ; BLUE-C Study Investigators. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14;390(11):984-993. doi: 10.1056/NEJMoa2310336. PubMed 38477986 ↗
  • Kim ER, Kwon HN, Nam H, Kim JJ, Park S, Kim YH. Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer. Sci Rep. 2019 Mar 18;9(1):4786. doi: 10.1038/s41598-019-41216-y. PubMed 30886205 ↗
  • Lo YMD. Cell-free DNA for Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14;390(11):1047-1050. doi: 10.1056/NEJMe2311101. No abstract available. PubMed 38477993 ↗
  • Luan Y, Zhong G, Li S, Wu W, Liu X, Zhu D, Feng Y, Zhang Y, Duan C, Mao M. A panel of seven protein tumour markers for effective and affordable multi-cancer early detection by artificial intelligence: a large-scale and multicentre case-control study. EClinicalMedicine. 2023 Jun 15;61:102041. doi: 10.1016/j.eclinm.2023.102041. eCollection 2023 Jul. PubMed 37387788 ↗
  • Pardini B, Ferrero G, Tarallo S, Gallo G, Francavilla A, Licheri N, Trompetto M, Clerico G, Senore C, Peyre S, Vymetalkova V, Vodickova L, Liska V, Vycital O, Levy M, Macinga P, Hucl T, Budinska E, Vodicka P, Cordero F, Naccarati A. A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study. Gastroenterology. 2023 Sep;165(3):582-599.e8. doi: 10.1053/j.gastro.2023.05.037. Epub 2023 May 30. PubMed 37263306 ↗
  • Wang H, Tso V, Wong C, Sadowski D, Fedorak RN. Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps. Clin Transl Gastroenterol. 2014 Mar 20;5(3):e54. doi: 10.1038/ctg.2014.2. PubMed 24646506 ↗
  • Wisse PHA, de Klaver W, van Wifferen F, van Maaren-Meijer FG, van Ingen HE, Meiqari L, Huitink I, Bierkens M, Lemmens M, Greuter MJE, van Leerdam ME, Spaander MCW, Dekker E, Coupe VMH, Carvalho B, de Wit M, Meijer GA. The multitarget faecal immunochemical test for improving stool-based colorectal cancer screening programmes: a Dutch population-based, paired-design, intervention study. Lancet Oncol. 2024 Mar;25(3):326-337. doi: 10.1016/S1470-2045(23)00651-4. Epub 2024 Feb 9. PubMed 38346438 ↗
  • Zhao F, Bai P, Xu J, Li Z, Muhammad S, Li D, Zhang Z, Gao Y, Liu Q. Efficacy of cell-free DNA methylation-based blood test for colorectal cancer screening in high-risk population: a prospective cohort study. Mol Cancer. 2023 Sep 28;22(1):157. doi: 10.1186/s12943-023-01866-z. PubMed 37770864 ↗
  • Zhang Z, Liu X, Yang X, Jiang Y, Li A, Cong J, Li Y, Xie Q, Xu C, Liu D. Identification of faecal extracellular vesicles as novel biomarkers for the non-invasive diagnosis and prognosis of colorectal cancer. J Extracell Vesicles. 2023 Jan;12(1):e12300. doi: 10.1002/jev2.12300. PubMed 36604402 ↗
  • Wender R, Brooks D, Sharpe K, Doroshenk M. The National Colorectal Cancer Roundtable: Past Performance, Current and Future Goals. Gastrointest Endosc Clin N Am. 2020 Jul;30(3):499-509. doi: 10.1016/j.giec.2020.02.013. Epub 2020 Apr 16. PubMed 32439084 ↗

Individual participant data

Plan to share: Undecided — Data collected for the study will be made available to others, including de-identified participant data, at publication, via a signed data access agreement and at the discretion of the investigators' approval of the proposed use of such data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2020 (actual). Primary completion is estimated for Jun 2028, 99 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 2, 2024
StartActual
Mar 15, 2020
Primary completionEst.
Jun 18, 2028
CompletionEst.
Jun 18, 2028
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06342440
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Mar 15, 2020
Primary completion
Jun 18, 2028 (estimated)
Completion
Jun 18, 2028 (estimated)
Last update
Jul 7, 2026

Study contacts

Ajay Goel, PhD
Contact
AJGOEL@COH.ORG
6262183452
Ajay Goel, PhD
principal investigator · City of Hope Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion